Fujifilm Corporation has rebranded its Life Sciences Group companies as part of a strategic positioning effort.
The new names, collaborative strategic focus, and structural alignment reflects Fujifilm's commitment to life cciences, offering fully integrated, end-to-end solutions across the drug development life cycle.
Santa Ana, California-based Fujifilm Irvine Scientific will become Fujifilm Biosciences under the new structure and strategy. The company will continue to offer a comprehensive portfolio of discovery and research reagents, recombinant growth factors and proteins, specialty chemicals, and critical assay materials in addition to its robust cell culture media and supplements solutions in the U.S.
Fujifilm Diosynth Biotechnologies, a global CDMO first acquired by the Fujifilm Group in 2011, will rebrand to Fujifilm Biotechnologies.
"By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector, where we believe that unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum. It is an opportunity to ensure the teams in all our Life Sciences companies share the same strategy and strong sense of purpose,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, Fujifilm Corp., Japan.
Alongside Fujifilm Biosciences and Fujifilm Biotechnologies, the Fujifilm Life Sciences Group companies also include Fujifilm Cellular Dynamics, a developer and manufacturer of human induced pluripotent stem cells, Fujifilm Wako Pure Chemical Corporation, and Fujifilm Toyama Chemical Co.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!